Abstract
Clinical caseA 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were administered. 12 months after the last intravitreal rituximab dose, signs and symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab administration were not observed. DiscussionIntravitreal rituximab is an effective and safe treatment of intravitreal lymphoma, by inducing complete remission; it could be a good alternative to other therapeutic options with greater number of serious complications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
